View Item 

Show simple item record

Stiripentol in D ravet syndrome: Results of a retrospective U . S . study
dc.contributor.authorWirrell, Elaine C.en_US
dc.contributor.authorLaux, Lindaen_US
dc.contributor.authorFranz, David N.en_US
dc.contributor.authorSullivan, Josephen_US
dc.contributor.authorSaneto, Russell P.en_US
dc.contributor.authorMorse, Richard P.en_US
dc.contributor.authorDevinsky, Orrinen_US
dc.contributor.authorChugani, Harryen_US
dc.contributor.authorHernandez, Angelen_US
dc.contributor.authorHamiwka, Lorieen_US
dc.contributor.authorMikati, Mohamad A.en_US
dc.contributor.authorValencia, Ignacioen_US
dc.contributor.authorLe Guern, Marie‐emmanuelleen_US
dc.contributor.authorChancharme, Laurenten_US
dc.contributor.authorMenezes, Marcio Soteroen_US
dc.date.accessioned2013-10-02T15:13:24Z
dc.date.available2014-10-06T19:17:43Zen_US
dc.date.issued2013-09en_US
dc.identifier.citationWirrell, Elaine C.; Laux, Linda; Franz, David N.; Sullivan, Joseph; Saneto, Russell P.; Morse, Richard P.; Devinsky, Orrin; Chugani, Harry; Hernandez, Angel; Hamiwka, Lorie; Mikati, Mohamad A.; Valencia, Ignacio; Le Guern, Marie‐emmanuelle ; Chancharme, Laurent; Menezes, Marcio Sotero (2013). "Stiripentol in D ravet syndrome: Results of a retrospective U . S . study." Epilepsia 54(9): 1595-1604. <http://hdl.handle.net/2027.42/100157>en_US
dc.identifier.issn0013-9580en_US
dc.identifier.issn1528-1167en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/100157
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherPediatric Epilepsyen_US
dc.subject.otherIntractable Epilepsyen_US
dc.subject.otherStiripentolen_US
dc.subject.otherD Ravet Syndromeen_US
dc.titleStiripentol in D ravet syndrome: Results of a retrospective U . S . studyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23848835en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/100157/1/epi12303.pdf
dc.identifier.doi10.1111/epi.12303en_US
dc.identifier.sourceEpilepsiaen_US
dc.identifier.citedreferenceNabbout R, Copioli C, Chipaux M, Chemaly N, Desguerre I, Dulac O, Chiron C. ( 2011 ) Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia 52: e54 – e57.en_US
dc.identifier.citedreferenceLaurie DJ, Wisden W, Seeburg PH. ( 1992 ) The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J Neurosci 12: 4151 – 4172.en_US
dc.identifier.citedreferenceTanabe T, Awaya Y, Matsuishi T, Iyoda K, Nagai T, Kurihara M, Yamamoto K, Minagawa K, Maekawa K. ( 2008 ) Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)–a nationwide questionnaire survey in Japan. Brain Dev 30: 629 – 635.en_US
dc.identifier.citedreferenceSkluzacek JV, Watts KP, Parsy O, Wical B, Camfield P. ( 2011 ) Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia 52 ( Suppl. 2 ): 95 – 101.en_US
dc.identifier.citedreferenceSakauchi M, Oguni H, Kato I, Osawa M, Hirose S, Kaneko S, Takahashi Y, Takayama R, Fujiwara T. ( 2011 ) Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia 52: 1144 – 1149.en_US
dc.identifier.citedreferenceRagona E. ( 2011 ) Cognitive development in children with Dravet syndrome. Epilepsia 52 ( Suppl. 2 ): 39 – 43.en_US
dc.identifier.citedreferenceAkiyama M, Kobayashi K, Yoshinaga H, Ohtsuka Y. ( 2010 ) A long‐term follow‐up study of Dravet syndrome up to adulthood. Epilepsia 51: 1043 – 1052.en_US
dc.identifier.citedreferenceBrunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. ( 2012 ) Prognostic, clinical and demographic features in SCN1A mutation‐positive Dravet syndrome. Brain 135: 2329 – 2336.en_US
dc.identifier.citedreferenceCaraballo RH. ( 2011 ) Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia 52 ( Suppl. 2 ): 79 – 82.en_US
dc.identifier.citedreferenceCeulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG, Lagae L. ( 2012 ) Successful use of fenfluramine as an add‐on treatment for Dravet syndrome. Epilepsia 53: 1131 – 1139.en_US
dc.identifier.citedreferenceChiron C, Dulac O. ( 2011 ) The pharmacologic treatment of Dravet syndrome. Epilepsia 52 ( Suppl. 2 ): 72 – 75.en_US
dc.identifier.citedreferenceChiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G. ( 2000 ) Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo‐controlled syndrome‐dedicated trial. STICLO study group. Lancet 356: 1638 – 1642.en_US
dc.identifier.citedreferenceCoppola G, Capovilla G, Montagnini A, Romeo A, Spano M, Tortorella G, Veggiotti P, Viri M, Pascotto A. ( 2002 ) Topiramate as add‐on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res 49: 45 – 48.en_US
dc.identifier.citedreferenceFisher JL. ( 2009 ) The anti‐convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology 56: 190 – 197.en_US
dc.identifier.citedreferenceFisher JL. ( 2011 ) Interactions between modulators of the GABA(A) receptor: stiripentol and benzodiazepines. Eur J Pharmacol 654: 160 – 165.en_US
dc.identifier.citedreferenceGenton P, Velizarova R, Dravet C. ( 2011 ) Dravet syndrome: the long‐term outcome. Epilepsia 52 ( Suppl. 2 ): 44 – 49.en_US
dc.identifier.citedreferenceGiraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, Tran A. ( 2006 ) In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 34: 608 – 611.en_US
dc.identifier.citedreferenceGrosenbaugh DK, Mott DD. ( 2013 ) Stiripentol is anticonvulsant by potentiating GABAergic transmission in a model of benzodiazepine‐refractory status epilepticus. Neuropharmacology 67: 136 – 143.en_US
dc.identifier.citedreferenceInoue Y, Ohtsuka Y, Oguni H, Tohyama J, Baba H, Fukushima K, Ohtani H, Takahashi Y, Ikeda S. ( 2009 ) Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 50: 2362 – 2368.en_US
dc.identifier.citedreferenceQuilichini PP, Chiron C, Ben‐Ari Y, Gozlan H. ( 2006 ) Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA‐A receptor channels. Epilepsia 47: 704 – 716.en_US
dc.identifier.citedreferenceKang HC, Kim YJ, Kim DW, Kim HD. ( 2005 ) Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia 46: 272 – 279.en_US
dc.identifier.citedreferenceTran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH. ( 1997 ) Influence of stiripentol on cytochrome P450‐mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 62: 490 – 504.en_US
dc.identifier.citedreferenceThanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, Dulac O. ( 2002 ) Long‐term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome). Arch Pediatr 9: 1120 – 1127.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
epi12303.pdf
Size:
103.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.